Eton Pharma buys US commercialization rights to leishmaniasis drug Impavido from Knight affiliate
PUBT · 3h ago
Share
Listen to the news
- Eton Pharmaceuticals signed a supply and distribution agreement to acquire exclusive U.S. commercialization rights to IMPAVIDO (miltefosine) from a Knight Therapeutics affiliate.
- The rights take effect on Sep. 26, 2026, adding another planned 2026 product launch to Eton’s rare-disease portfolio.
- IMPAVIDO is the only FDA-approved oral therapy for certain forms of leishmaniasis, a rare parasitic disease that can be life-threatening if untreated.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017799), on May 19, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved